[Click eStock] Humedics Maintains Target Price at 33,000 Won

[Asia Economy Reporter Junho Hwang] SangSangIn Securities maintained the target price of Humedix at 33,000 KRW on the 22nd. It is evaluated as a stock that can be approached from a buying perspective when the interest rate hike peaks out.

Researcher Taegi Ha of SangSangIn Securities stated, "The stock price of Humedix rose to the 40,000 KRW range at the end of April 2021 due to expectations of producing the Russian COVID vaccine, but since then, as expectations for production disappeared, it has fallen to the 20,000 KRW range currently," and analyzed, "The price-to-earnings ratio (PER) based on this year's estimated performance (excluding equity sale gains) is around 9 times, and the market capitalization is about 200 billion KRW."

This year, with the 'With Corona' policy, sales of high-margin main products grew rapidly, resulting in significant profit growth, and going forward, there is a high possibility of external growth with the launch of PN arthritis products (2023), PDRN complex fillers (2024), and heparin sodium raw materials (2023).

Researcher Ha explained, "It seems very likely that Humedix's future operating profit margin will improve to the 20% range," adding, "The domestic and international aesthetic markets are expected to expand and grow rapidly, so the future growth potential is large."

This content was produced with the assistance of AI translation services.